Insilico Medicine Raises HKD 2.3 Billion in Record Hong Kong Biotech IPO to Scale AI-Driven Drug R&D

New updates have been reported about Insilico Medicine.

Insilico Medicine has listed on the Main Board of the Hong Kong Stock Exchange under stock code 3696.HK, raising HKD 2.277 billion in the city’s largest biotech IPO of 2025 and becoming the first AI‑driven biotech to go public under Chapter 8.05. The offering, jointly sponsored by Morgan Stanley, CICC and GF Securities, was heavily oversubscribed, with the Hong Kong public tranche oversubscribed by about 1,427 times and the international placement by 26 times, attracting over HKD 328 billion in locked subscription funds and drawing 15 cornerstone investors including Lilly, Tencent, Temasek, Schroders, UBS AM, Oaktree and major Chinese asset managers. Management, led by Founder and CEO Alex Zhavoronkov and Co‑CEO/CSO Feng Ren, positions the listing as both capital and strategic validation of Insilico’s end‑to‑end AI drug discovery platform, Pharma.AI, which underpins collaborations with 13 of the world’s top 20 pharma companies, three out‑licensing deals with an aggregate potential value of up to US$2.1 billion, and a pipeline of more than 30 programs, 10 of which have IND clearance and seven in active clinical development.

The company plans to deploy approximately 48% of IPO proceeds into advancing key clinical‑stage assets, 20% into earlier‑stage discovery programs, 15% into new generative AI models and validation, 12% into expanding its fully automated “Life Star” laboratory network, and 5% for working capital and general corporate purposes. Insilico has already demonstrated materially compressed early‑stage timelines, cutting average time from program start to preclinical candidate to 12–18 months with limited molecule synthesis per program, and has advanced its lead AI‑discovered IPF candidate, Rentosertib, through Phase IIa in China with dose‑dependent efficacy signals and favorable safety published in Nature Medicine. The company is also driving its Pharmaceutical Superintelligence concept, using purpose‑built models and proprietary multimodal data to extend AI capabilities across fibrosis, oncology, immunology, inflammation, cardiometabolics, CNS and adjacent sectors such as advanced materials and agriculture. With a highly credentialed, AI‑and‑drug‑development dual‑engine leadership structure and a strong academic and IP record, Insilico aims to use its strengthened balance sheet and global investor base to accelerate clinical execution, expand its platform’s commercial footprint, and push for a broader paradigm shift toward AI‑first drug discovery and development worldwide.